UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 0-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR OT ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q1 2021 Earnings Conference Call April 28, 2021 8:30 AM ET Company Participants Mike Beaulieu – Head of Investor Relations Peter Arduini – President and Chief Executive Officer Glenn Coleman – Chief Operating Officer Carrie Anderson – Chief Financial Officer Conference Call Participants Shagun Singh – Wells Fargo Ryan Zimmerman – BTIG Dave Turkaly – JPM Securities Kaila Krum – Truist Securities Robbie Marcus – JPMorgan Steven Lichtman – Oppenheimer & C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 0-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR OTHER J ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q4 2020 Earnings Conference Call February 18, 2021 8:30 AM ET Company Participants Mike Beaulieu - Director, Investor Relations Peter Arduini - President & Chief Executive Officer Carrie Anderson - Chief Financial Officer Glenn Coleman - Chief Operating Officer Conference Call Participants Matt Miksic - Credit Suisse Dave Turkaly - JMP Securities Kaila Krum - Truist Securities Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler Matt Taylor - UBS S ...

Q4 2020 Earnings Call Q4 2019 Earnings Call February 24, 2020 February 18, 2021 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forwardlooking statements. Some of these forward-looking statements may contai ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%2E%20FINANCIAL%20INFORMATION) This section provides comprehensive financial data, including statements, notes, and management's analysis, for the period ended September 30, 2020 [Financial Statements](index=4&type=section&id=Item%201%2E%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2020, and 2019, along with detailed notes [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported a net income of $32.3 million for Q3 2020, a significant turnaround from a net loss of $27.6 million in Q3 2019, largely due to the absence of a $59.9 million IPR&D expense Consolidated Statement of Operations Highlights (In thousands, except per share amounts) | Metric | Three Months Ended Sep 30, 2020 | Three Months Ended Sep 30, 2019 | Nine Months Ended Sep 30, 2020 | Nine Months Ended Sep 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Total revenue, net | $370,232 | $379,095 | $983,221 | $1,122,430 | | Operating income (loss) | $57,542 | $(20,587) | $98,725 | $57,680 | | Net income (loss) | $32,337 | $(27,610) | $41,148 | $34,882 | | Diluted EPS | $0.38 | $(0.32) | $0.48 | $0.40 | [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of September 30, 2020, total assets were $3.45 billion, up from $3.30 billion at year-end 2019, driven by increased cash and the classification of assets held for sale Consolidated Balance Sheet Highlights (In thousands) | Metric | September 30, 2020 | December 31, 2019 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $396,279 | $198,911 | | Assets held for sale | $159,977 | $— | | Total assets | $3,453,521 | $3,303,240 | | **Liabilities & Equity** | | | | Long-term convertible securities | $469,898 | $— | | Total liabilities | $2,055,534 | $1,886,504 | | Total stockholders' equity | $1,397,987 | $1,416,736 | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the nine months ended September 30, 2020, net cash from operating activities decreased to $123.6 million, while financing activities provided $100.4 million, driven by convertible note issuance Consolidated Statement of Cash Flows Highlights (In thousands) | Metric | Nine Months Ended Sep 30, 2020 | Nine Months Ended Sep 30, 2019 | | :--- | :--- | :--- | | Net cash provided by operating activities | $123,570 | $142,249 | | Net cash used in investing activities | $(32,152) | $(142,059) | | Net cash provided by financing activities | $100,403 | $73,226 | | Net increase in cash and cash equivalents | $197,368 | $69,143 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes provide detailed explanations of the financial statements, covering COVID-19 impact, the planned divestiture of Extremity Orthopedics, debt, and derivative activities - The company is subject to risks from the COVID-19 pandemic, which caused customers to defer or cancel elective procedures, though volumes began to approach normalized levels through Q3 2020, ongoing uncertainty persists[24](index=24&type=chunk) - On September 29, 2020, the company agreed to sell its Extremity Orthopedics business to Smith & Nephew for approximately **$240 million in cash**, with assets and liabilities now classified as held for sale[35](index=35&type=chunk) - On February 4, 2020, the company issued **$575.0 million of 0.5% Convertible Senior Notes due 2025**, entering into call and warrant transactions to effectively increase the conversion price[93](index=93&type=chunk)[96](index=96&type=chunk) Disaggregated Revenue (In thousands) | Revenue Source | Three Months Ended Sep 30, 2020 | Nine Months Ended Sep 30, 2020 | | :--- | :--- | :--- | | **Codman Specialty Surgical** | $239,323 | $640,541 | | **Orthopedics and Tissue Technologies** | $130,909 | $342,680 | | **Total revenue** | **$370,232** | **$983,221** | [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=50&type=section&id=Item%202%2E%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, highlighting the COVID-19 impact, strategic priorities, and segment results, along with liquidity and capital resources - The company's strategic priorities include strategic acquisitions, portfolio optimization, new product introductions, and commercial channel investments[178](index=178&type=chunk)[179](index=179&type=chunk)[180](index=180&type=chunk) - The sale of the Extremity Orthopedics business is expected to make Integra a faster-growing, more profitable, and more focused company, allowing for increased investment in core Neurosurgery and Tissue Technology businesses[181](index=181&type=chunk) - In response to COVID-19, the company implemented cost-saving measures in April 2020, including reduced compensation and discretionary spending, which were restored in Q3 as revenues recovered[189](index=189&type=chunk) [Results of Operations](index=54&type=section&id=MD%26A-Results%20of%20Operations) For Q3 2020, total revenues decreased 2.3% YoY to $370.2 million, a significant improvement from Q2, with net income of $32.3 million due to the absence of a prior-year IPR&D expense Revenue by Segment (In thousands) | Segment | Q3 2020 Revenue | Q3 2019 Revenue | % Change | | :--- | :--- | :--- | :--- | | Codman Specialty Surgical | $239,323 | $252,984 | -5.4% | | Orthopedics & Tissue Technologies | $130,909 | $126,111 | +3.8% | | **Total Revenue** | **$370,232** | **$379,095** | **-2.3%** | - Q3 2020 gross margin increased to **63.6%** from **62.4%** in Q3 2019, attributed to favorable revenue mix and cost-saving measures[217](index=217&type=chunk) - Q3 2020 operating expenses decreased by **$79.2 million** YoY, primarily due to a **$59.9 million** IPR&D expense in Q3 2019 and a **$23.0 million** reduction in SG&A costs from cost-saving measures and lower sales commissions[218](index=218&type=chunk)[219](index=219&type=chunk)[220](index=220&type=chunk) [Liquidity and Capital Resources](index=62&type=section&id=MD%26A-Liquidity%20and%20Capital%20Resources) Cash and cash equivalents increased to $396.3 million at September 30, 2020, primarily driven by financing activities, including the issuance of $575.0 million in convertible senior notes - Cash and cash equivalents increased to **$396.3 million** at Sept 30, 2020 from **$198.9 million** at Dec 31, 2019[248](index=248&type=chunk) - Net cash from operating activities was **$123.6 million** for the first nine months of 2020, a decrease from **$142.2 million** in the prior year period, mainly due to an increase in inventory[249](index=249&type=chunk)[250](index=250&type=chunk) - During the first nine months of 2020, the company repurchased **2.1 million shares** for **$100.0 million**, with **$125.0 million** remaining under the share repurchase authorization as of September 30, 2020[260](index=260&type=chunk)[261](index=261&type=chunk) Contractual Obligations as of September 30, 2020 (In millions) | Obligation | Total | Payments Due 2021-2022 | Payments Due Thereafter | | :--- | :--- | :--- | :--- | | Revolving Credit Facility | $97.5 | $— | $97.5 | | Term Loan | $877.5 | $78.8 | $798.7 | | Securitization Facility | $92.3 | $92.3 | $— | | Convertible Debt | $575.0 | $— | $575.0 | | Operating Leases | $140.4 | $27.0 | $109.6 | [Quantitative and Qualitative Disclosures About Market Risk](index=66&type=section&id=Item%203%2E%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exposed to market risks from foreign currency exchange rates and interest rates on its variable-rate debt, mitigated by derivative instruments - The company is primarily exposed to foreign currency exchange rate risk with respect to transactions in EUR, GBP, CHF, and other currencies[277](index=277&type=chunk) - To manage interest rate risk on its LIBOR-indexed borrowings, the company uses interest rate swaps, with a total notional amount of **$975.0 million** in effect as of September 30, 2020[282](index=282&type=chunk)[283](index=283&type=chunk) - A hypothetical **100 basis point** change in interest rates would have impacted annual interest expense on the unhedged portion of the debt by **$0.9 million**[283](index=283&type=chunk) [Controls and Procedures](index=66&type=section&id=Item%204%2E%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of September 30, 2020, with no material changes to internal control over financial reporting during the quarter - The Principal Executive Officer and Principal Financial Officer concluded that the company's disclosure controls and procedures were effective as of September 30, 2020[286](index=286&type=chunk) - There were no changes in internal control over financial reporting during the quarter ended September 30, 2020, that have materially affected, or are reasonably likely to materially affect, internal controls[287](index=287&type=chunk) [PART II. OTHER INFORMATION](index=67&type=section&id=PART%20II%2E%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity security sales, and other required disclosures [Legal Proceedings](index=67&type=section&id=Item%201%2E%20Legal%20Proceedings) This section refers to Note 17, "Commitment and Contingencies," for information on legal proceedings, which are not expected to have a material adverse effect on financial condition - Information on legal proceedings is located in Note 17, which states that such claims are not expected to have a material adverse effect on the company's financial condition[165](index=165&type=chunk)[289](index=289&type=chunk) [Risk Factors](index=67&type=section&id=Item%201A%2E%20Risk%20Factors) This section adds new risk factors related to the pending sale of the Extremity Orthopedics business, including completion risk, business disruption, and impact on relationships - The sale of the Extremity Orthopedics business is subject to customary closing conditions, including an employee consultation process in France, and may not be completed on a timely basis or at all[291](index=291&type=chunk) - The pending sale may disrupt business, adversely affect relationships with employees and business partners, and divert management's attention[292](index=292&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=67&type=section&id=Item%202%2E%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section refers to Note 12, "Treasury Stock," for information regarding the company's share repurchase program - Refers to Note 12 for information on the common stock repurchase program[294](index=294&type=chunk) [Mine Safety Disclosures](index=67&type=section&id=Item%204%2E%20Mine%20Safety%20Disclosures) The company states that this item is not applicable - Not applicable[295](index=295&type=chunk) [Other Information](index=67&type=section&id=Item%205%2E%20Other%20Information) The company states that this item is not applicable - Not applicable[296](index=296&type=chunk) [Exhibits](index=68&type=section&id=Item%206%2E%20Exhibits) This section lists the exhibits filed with the 10-Q report, including the Put Option Agreement for the sale of the Extremity Orthopedics business, CEO/CFO certifications, and XBRL data files - Lists filed exhibits, including the Put Option Agreement with Smith & Nephew, Sarbanes-Oxley certifications, and XBRL data files[303](index=303&type=chunk)

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or COMMISSION FILE NO. 0-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR OTH ...

Financial Performance - Net income for Q1 2020 was $9.2 million, or $0.11 per diluted share, down from $32.8 million, or $0.38 per diluted share in Q1 2019 [179]. - Total revenues for Q1 2020 were $354 million, a decline of 1.5% from $359.7 million in Q1 2019 [183]. - Total revenue for the three months ended March 31, 2020, was $354.3 million, a decrease of 1.0% from $359.7 million in the same period of 2019 [212]. - Domestic revenues decreased to $246.9 million, down from $256.7 million year-over-year, primarily due to the adverse effects of the COVID-19 pandemic [213]. - Codman Specialty Surgical segment revenues were $231.4 million, a decrease of $3.1 million, or 1.3% from the prior year [195]. - Orthopedics and Tissue Technologies segment revenues were $122.9 million, a decrease of $2.2 million, or 1.8% from the prior year [196]. - Gross margin decreased to $220.8 million, or 62.3% of total revenues, down from 64.2% in the same period last year [197]. - Operating expenses decreased by $4.7 million, or 2.4%, to $193.7 million in Q1 2020 compared to $198.5 million in Q1 2019 [198]. - Net cash provided by operating activities was $20.8 million for the three months ended March 31, 2020, down from $29.5 million in the same period of 2019 [215]. Impact of COVID-19 - Revenue decline in Q2 2020 is expected due to the impact of the COVID-19 pandemic, with uncertainty regarding the extent of the impact on surgical procedures [171]. - The estimated revenue impact from the decline in surgical procedures due to COVID-19 was approximately $20 to $25 million in Q1 2020 [183]. - The company expects a more substantial negative impact on Q2 performance due to ongoing restrictions from COVID-19 [183]. - The company anticipates materially lower sales as long as surgeries are deferred due to the COVID-19 pandemic, impacting future revenue forecasts [222]. - The company implemented significant cost-saving measures in response to COVID-19, including reduced executive compensation and a hiring freeze [171]. Research and Development - In 2019, the company launched ten new products across key product franchises, focusing on innovative product development [165]. - The company continues to prioritize investments in R&D and clinical programs despite cost-reduction measures due to COVID-19 [171]. - Research and development expenses increased by $2.5 million primarily due to product development costs related to a new acquisition [199]. Acquisitions and Strategic Initiatives - The Codman Neurosurgery acquisition in 2019 expanded the company's portfolio and established it as a world leader in neurosurgery [164]. - The company is focused on strategic acquisitions and licensing agreements to increase relevant scale in clinical areas [164]. - The Company has an option to acquire Integrated Shoulder Collaboration Inc. for up to $80.0 million, contingent on achieving certain sales thresholds [235]. Financial Obligations and Capital Management - Total contractual obligations as of March 31, 2020, amounted to $1.95 billion, with significant payments due in the coming years [231]. - The Company issued $575.0 million of 0.5% Convertible Senior Notes due 2025, maturing on August 15, 2025 [233]. - The company repurchased 1.4 million shares of common stock during the three months ended March 31, 2020, utilizing $100 million from the offering of Convertible Senior Notes [224]. - The company has $125 million remaining under its share repurchase authorization, with future purchases dependent on cash generation and market conditions [225]. - Capital expenditures for the three months ended March 31, 2020, were $16.5 million, primarily directed to facility expansions and new product development [217]. Tax and Interest Rates - The effective tax rate for Q1 2020 was 19.8%, compared to an effective tax rate of -32.0% in Q1 2019 [204]. - The company expects an effective income tax rate of approximately (14.6)% for the full year, primarily due to a projected pretax loss from the impact of COVID-19 [208]. - Interest expense increased by $4.6 million compared to the same period last year, primarily due to the issuance of Convertible Senior Notes [202]. - A hypothetical 100 basis point movement in interest rates would increase interest income by approximately $3.6 million annually on cash and cash equivalents [245]. - A 100 basis point change in interest rates would impact interest expense on the unhedged portion of the debt by $2.3 million on an annualized basis [247]. Currency and Financial Instruments - The Company is exposed to foreign currency exchange rate risks primarily with respect to transactions in Euros, British pounds, and other currencies [241]. - The Company manages foreign currency exposure through derivative financial instruments, including foreign currency exchange forward contracts [242]. Other Financial Metrics - Cash and cash equivalents increased to approximately $357.7 million as of March 31, 2020, compared to $198.9 million at December 31, 2019 [214]. - The liability for uncertain tax benefits totaled $0.8 million at March 31, 2020 [237]. - The estimated fair value of contingent consideration obligations related to acquisitions was $13.4 million as of March 31, 2020 [234]. - The total notional amount of interest rate swaps in effect as of March 31, 2020 was $900 million [247]. - The Company has excluded future pension contribution obligations from its contractual obligations due to uncertainty in payment amounts and dates [236].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. EMPLOYER IDENTIFICATION NO.) 1100 Campus Road 08540 Princeton , New Jersey (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (609) 275-0500 SECUR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 0-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE O ...